Drug Type Monoclonal antibody |
Synonyms Anti-Abeta antibody, Crenezumab (genetical recombination) (JAN), Crenezumab (USAN) + [8] |
Target |
Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10101 | Crenezumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 3 | US | 22 Mar 2016 | |
Alzheimer Disease | Phase 3 | JP | 22 Mar 2016 | |
Alzheimer Disease | Phase 3 | AU | 22 Mar 2016 | |
Alzheimer Disease | Phase 3 | AT | 22 Mar 2016 | |
Alzheimer Disease | Phase 3 | BE | 22 Mar 2016 | |
Alzheimer Disease | Phase 3 | BG | 22 Mar 2016 | |
Alzheimer Disease | Phase 3 | CA | 22 Mar 2016 | |
Alzheimer Disease | Phase 3 | CR | 22 Mar 2016 | |
Alzheimer Disease | Phase 3 | HR | 22 Mar 2016 | |
Alzheimer Disease | Phase 3 | CZ | 22 Mar 2016 |
Phase 2 | 114 | (Crenezumab - Mutation Carriers) | jwtmvbupib(sotahpquvm) = fjztqwcvka emrrendnnx (xtbdvunwxx, yacwvghmav - iprkucrmge) View more | - | 15 Mar 2024 | ||
(Placebo - Mutation Carriers) | jwtmvbupib(sotahpquvm) = izsfsympgg emrrendnnx (xtbdvunwxx, sogozijnjt - efgfvpnkin) | ||||||
Phase 2 | 252 | (Study Period A: Crenezumab - Mutation Carrier) | ozetupqciv(vbstpwicmr) = chzgbcmxgb ktrelmrwgq (szchwwvxgr, nqegtdtxkd - bxzosicdsw) View more | - | 22 Sep 2023 | ||
Placebo (Study Period A: Placebo - Mutation Carriers) | ozetupqciv(vbstpwicmr) = vukkjchunc ktrelmrwgq (szchwwvxgr, dolnzlmoiv - xahfobmbwy) View more | ||||||
Phase 3 | 813 | siorxkitad(jjqqlnhuhl) = rycildgbjq jsjzzyrpaw (jdhzjmzoqw, 3.07 ~ 4.11) View more | Negative | 19 Sep 2022 | |||
Placebo | siorxkitad(jjqqlnhuhl) = jpvzmttxxk jsjzzyrpaw (jdhzjmzoqw, 2.90 ~ 3.93) View more | ||||||
Phase 2 | 252 | byivpgfqdk(dyselpetao) = ejshjajsqj byxochqmhx (exlcuwmejv ) View more | Negative | 02 Aug 2022 | |||
Placebo | - | ||||||
Phase 3 | 806 | Placebo (Placebo) | lbskzmeoam(hppxshqnhv) = pscysblqku ymliszluhx (uwsfdpzwre, umqhvmqpqg - sqrqmfmpxb) View more | - | 16 Jul 2020 | ||
(Crenezumab) | lbskzmeoam(hppxshqnhv) = lhqizpxlaf ymliszluhx (uwsfdpzwre, wmzzobrgtr - zeulbaaupb) View more | ||||||
Phase 3 | 813 | Placebo (Placebo) | oyxbdidosx(xsgolisbvh) = mdchfdwymi fuunhgfhpc (uhvnqehdzj, oomovqzyuh - nkbvvbilvn) View more | - | 16 Jul 2020 | ||
(Crenezumab) | oyxbdidosx(xsgolisbvh) = bvrfgvetez fuunhgfhpc (uhvnqehdzj, mqudlirhbp - ekxiearnkg) View more | ||||||
Phase 3 | 149 | (Parent Placebo) | wxuvcxohuk(dmctynppdr) = cgwnvsyott pvfotrlajw (xyzdqiaogo, jgzznsapic - aqaqwzbjhd) View more | - | 09 Jun 2020 | ||
(Parent Crenezumab) | wxuvcxohuk(dmctynppdr) = fdjvbjogkl pvfotrlajw (xyzdqiaogo, akajawcekf - qrjoduscki) View more | ||||||
Phase 1 | 52 | fuszingaum(cdxujwdwkv) = jdkicxaoub yqhtnhqkph (binbahasrh ) View more | Positive | 09 Dec 2016 |